https://www.selleckchem.com/pr....oducts/adavivint.htm
Detecting patients with DPD deficiency is becoming a major concern in clinical oncology. Monitoring physiological plasma uracil and/or plasma uracil-to-dihydrouracil metabolic ratio is a common surrogate frequently used to determine DPD phenotype without direct measurement of the enzymatic activity. With respect to the rising number of patients to be analyzed, developing simple, rapid and affordable methods suitable to routine screening is critical. We have developed and validated a simple and robust UPLC-UV method with shorten (i.e.,
Like
Comment
Share
